Drugs / PEPTIDE YY HUMAN (3-36)
PEPTIDE YY HUMAN (3-36)
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02493959 | May 2014 → Jul 2015 | — | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT03490786 | Jul → Aug 2017 | eating disorder | Gila Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00468884 | Oct 2006 → Feb 2007 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT00331175 | Jul → Dec 2006 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00537420 | Oct 2007 → Jul 2008 | obesity disorder | Nastech Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00940134 | Mar 2011 → Jan 2012 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| — | NCT00259233 | Mar → May 2005 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEPTIDE YY HUMAN (3-36) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297971 ↗ |
| Known as | GT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03490786 ↗ |
| Known as | Peptide YY3-36 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00331175 ↗ |
| Known as | PYY 3-36 | “12 obese subjects will receive peripheral administration of placebo and 4 escalating doses of PYY1-36 and another 12 obese subjects will receive peripheral administration of...” NCT00259233 ↗5“Our aim was to examine the effects of GLP-1 and PYY3-36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism,...” PMID 24735885 ↗ Apr 2014 “Biological: PYY 3-36” NCT00940134 ↗ |
| Action | Activate | “Neuropeptide Y receptor type 2 agonist” CHEMBL4297971 ↗ |
| Modality | Peptide | “Peptide YY3-36” NCT00331175 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT00331175 ↗ |
| Target | NPY2R | “Neuropeptide Y receptor type 2 agonist” CHEMBL4297971 ↗ |